120 filings
8-K
LRMR
Larimar Therapeutics Inc
31 May 24
Submission of Matters to a Vote of Security Holders
4:07pm
8-K
LRMR
Larimar Therapeutics Inc
30 May 24
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
4:08pm
8-K
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
8-K
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
8-K
LRMR
Larimar Therapeutics Inc
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
74936
11 Mar 24
Other Events
4:09pm
8-K
xm4c5d2a75jcb
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
8-K
2yu30 diefqu248
14 Feb 24
Termination of a Material Definitive Agreement
6:06am
8-K
02n9moqvw6fu
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
3yogkj5rvxbe g25
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
o78pu9l
3 Oct 23
Departure of Directors or Certain Officers
4:31pm
8-K
u7j2hl4
14 Aug 23
Other Events
8:00am
8-K
siy1gdc2pzuy 4b4bz
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
gxn0iobbn4
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
306c0ltwm8kqg c1ns
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
8-K
vlof nu1pbb6v
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
6a2t9
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
c8oxph
12 May 23
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
dr25i12o 4aa0hl2
6 Apr 23
Departure of Directors or Certain Officers
4:06pm
8-K
xt1yh
14 Mar 23
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
7:32am